Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, July 26 '25)

Image
By G.M.

 


    Am J Respir Crit Care Med

  1. LAUTRETTE A, Cadoret M, Richard JC, Schwebel C, et al
    Impact of Visitation Restrictions in ICU on Psychological Symptoms in Family Members: Experience of the COVID-19 Pandemic.
    Am J Respir Crit Care Med. 2025 Jul 23. doi: 10.1164/rccm.202412-2470.
    PubMed         Abstract available


    Clin Infect Dis

  2. AKANDE ET, Fowotade AA, Odih EE, Oaikhena AO, et al
    Genomic Surveillance of SARS-CoV-2 in Ibadan, Oyo State, Nigeria.
    Clin Infect Dis. 2025;80.
    PubMed         Abstract available

  3. STREINU-CERCEL A, Castagna A, Chang SC, Chen YS, et al
    Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients with COVID-19 (BIRCH): a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study.
    Clin Infect Dis. 2025 Jul 22:ciaf406. doi: 10.1093.
    PubMed         Abstract available

  4. BOSCOLO-RIZZO P, Spinato G, De Colle R, Maniaci A, et al
    Five-Year Longitudinal Assessment of Self-reported COVID-19-Related Chemosensory Dysfunction.
    Clin Infect Dis. 2025 Jul 23:ciaf331. doi: 10.1093.
    PubMed        

  5. SUBIDO-CARINO MT, Donadel M, Asi LD, Ariola-Ramos MS, et al
    Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence, Illness Recall, and Work Absenteeism Among Healthcare Workers: A Facility-Based Cross-Sectional Study in the Philippines, 2021.
    Clin Infect Dis. 2025 Jul 23:ciaf342. doi: 10.1093.
    PubMed         Abstract available

  6. MA KC, Surie D, Zhu Y, Grijalva CG, et al
    Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults with Respiratory Syncytial Virus.
    Clin Infect Dis. 2025 Jul 24:ciaf405. doi: 10.1093.
    PubMed         Abstract available

  7. CHISSUMBA RM, Kwatra G, Ramgi P, Enosse M, et al
    Hybrid Immunity in a Mozambican Cohort After 1 or 2 Doses of the BBIBP-CorV Vaccine.
    Clin Infect Dis. 2025;80.
    PubMed         Abstract available

  8. KANG SSY, Tadesse BT, Jeon HJ, Fallah MP, et al
    Enhancing Clinical Trial Sites in Low- and Middle-Income Countries to Facilitate Product Development in Response to the COVID-19 Pandemic.
    Clin Infect Dis. 2025;80.
    PubMed         Abstract available

  9. KIM CL, Thwe TT, Espinoza LMC, Sugimoto JD, et al
    Overcoming Vaccine Inequities and Research Gaps in Africa: Challenges and Opportunities Identified During the COVID-19 Pandemic.
    Clin Infect Dis. 2025;80.
    PubMed         Abstract available

  10. RAMGI P, Siribie M, Rakotozandrindrainy N, Bule O, et al
    Immunogenicity and Safety of Heterologous Versus Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique.
    Clin Infect Dis. 2025;80.
    PubMed         Abstract available

  11. RAKOTOZANDRINDRAINY N, Kang SSY, Wandji Nana LR, Sugimoto JD, et al
    COVID-19 Surveillance in Madagascar and Urban Burkina Faso: Addressing Underreporting of Disease Burden Through Integrative Analysis of Diverse Data Streams.
    Clin Infect Dis. 2025;80.
    PubMed         Abstract available

  12. CAPITINE IU, Aziz AB, Manhica A, Tivane I, et al
    Real-world Evaluation of the Effectiveness of Sinopharm COVID-19 Vaccine Against Symptomatic COVID-19 in an Omicron-Dominant Setting in Mozambique: A Test-Negative, Case-Control Study.
    Clin Infect Dis. 2025;80.
    PubMed         Abstract available

  13. DE SCHACHT C, Capitine IU, Lucas C, Muteerwa A, et al
    Importance of Targeted Communication Strategies During COVID-19 Vaccination Campaigns in Mozambique: Results of a Mixed-Methods Acceptability Study.
    Clin Infect Dis. 2025;80.
    PubMed         Abstract available


    Emerg Infect Dis

  14. LEGRAND NM, Bull RA, Hajarizadeh B, Lloyd AR, et al
    Surveillance of Viral Respiratory Infections within Maximum-Security Prison, Australia.
    Emerg Infect Dis. 2025;31:1527-1536.
    PubMed         Abstract available

  15. ROSE EB, Paden CR, Cook PW, Ma KC, et al
    Estimated COVID-19 Periodicity and Correlation with SARS-CoV-2 Spike Protein S1 Antigenic Diversity, United States.
    Emerg Infect Dis. 2025;31:1573-1579.
    PubMed         Abstract available

  16. PARK JS, Kim GJ, Lee SW
    Optimal Timing for Expanding Diagnostic Laboratories, South Korea.
    Emerg Infect Dis. 2025;31:1-8.
    PubMed         Abstract available

  17. WILSON-HENJUM G, Root JJ, Worgo A, Chandler J, et al
    Community-Scale Surveillance of SARS-CoV-2 and Influenza A Viruses in Wild Mammals, United States, 2022-2023.
    Emerg Infect Dis. 2025;31:1625-1629.
    PubMed         Abstract available

  18. HATTA M, Larson GP, Hatta Y, Wang W, et al
    ACE2 Receptor Usage across Animal Species by SARS-CoV-2 Variants.
    Emerg Infect Dis. 2025;31:1640-1644.
    PubMed         Abstract available

  19. JUDGE AS, Mitchell T, Klosovsky A, Weinberg M, et al
    COVID-19 Predeparture Test Results and Vaccination Coverage among US-Bound Refugees, 2020-2022.
    Emerg Infect Dis. 2025;31:1630-1635.
    PubMed         Abstract available

  20. BRADBURNE C, Islam A, Bird I, Abbott E, et al
    Genomic Surveillance Detection of SARS-CoV-1-Like Viruses in Rhinolophidae Bats, Bandarban Region, Bangladesh.
    Emerg Infect Dis. 2025;31:1652-1656.
    PubMed         Abstract available


    Int J Infect Dis

  21. ZHANG Y, Guo J, Li Y, Song Y, et al
    Pre-pregnancy vaccination with inactivated vaccines protects SARS-CoV-2-exposed neonates from respiratory distress.
    Int J Infect Dis. 2025 Jul 16:107978. doi: 10.1016/j.ijid.2025.107978.
    PubMed         Abstract available

  22. COBO-VAZQUEZ E, Aguilera-Alonso D, Grandioso-Vas D, Gamell A, et al
    SHARP INCREASE IN THE INCIDENCE AND SEVERITY OF INVASIVE STREPTOCOCCUS PYOGENES INFECTIONS IN CHILDREN AFTER THE COVID-19 PANDEMIC (2019-2023): A NATIONWIDE MULTICENTER STUDY.
    Int J Infect Dis. 2025 Jul 16:107982. doi: 10.1016/j.ijid.2025.107982.
    PubMed         Abstract available

  23. SIEBNER AS, Griesbaum J, Huus KE, Flugge J, et al
    Class switch towards IgG2 and IgG4 is more pronounced in BNT162b2 compared to mRNA-1273 COVID-19 vaccinees.
    Int J Infect Dis. 2025 Jul 16:107990. doi: 10.1016/j.ijid.2025.107990.
    PubMed         Abstract available


    J Infect

  24. ZHANG S, Liang H, Xu J, Chen B, et al
    Spatial-temporal Dynamics and Virus Interference of Respiratory Viruses: Insights from Multi-Pathogen Surveillance in China.
    J Infect. 2025 Jul 22:106556. doi: 10.1016/j.jinf.2025.106556.
    PubMed         Abstract available


    J Med Virol

  25. MASTERS EA, Tang W, Kang I, Kosikova M, et al
    Dissecting Sex-Specific Pathology in K18-hACE2 Transgenic Mice Infected With Different SARS-CoV-2 Variants.
    J Med Virol. 2025;97:e70506.
    PubMed         Abstract available

  26. HERNANDEZ-ORTIZ OH, Naranjo AF, Cadavid JJV, Echavez GR, et al
    Risk Factors for Breakthrough Acute SARS-CoV-2 Infections in Fully Vaccinated Individuals: A Case-Control Study Nested in a Prospective Cohort in Medelln, Colombia.
    J Med Virol. 2025;97:e70508.
    PubMed         Abstract available


    J Virol

  27. LI Q, Cai X, Li X, Zhang Y, et al
    Structural and functional constraints on spike activation and host protease utilization limit cell entry of SARS-CoV-2-related bat coronaviruses.
    J Virol. 2025 Jul 24:e0100725. doi: 10.1128/jvi.01007.
    PubMed         Abstract available


    JAMA

  28. SCHNEIDER L
    WHO Report Suggests Likely Zoonotic Origin of COVID-19, Doesn't Rule Out Lab Leak.
    JAMA. 2025 Jul 25. doi: 10.1001/jama.2025.10976.
    PubMed        


    Lancet

  29. APEAGYEI AE, Bisignano C, Elliott H, Hay SI, et al
    Tracking development assistance for health, 1990-2030: historical trends, recent cuts, and outlook.
    Lancet. 2025 Jul 14:S0140-6736(25)01240-1. doi: 10.1016/S0140-6736(25)01240.
    PubMed         Abstract available


  30. Global HIV targets: a roadmap to 2030 and beyond.
    Lancet. 2025 Jul 16:S0140-6736(25)01449-7. doi: 10.1016/S0140-6736(25)01449.
    PubMed        

  31. WINKLER AS, Brux CM, Carabin H, das Neves CG, et al
    The Lancet One Health Commission: harnessing our interconnectedness for equitable, sustainable, and healthy socioecological systems.
    Lancet. 2025 Jul 14:S0140-6736(25)00627-0. doi: 10.1016/S0140-6736(25)00627.
    PubMed        


    Nature

  32. CONROY G
    People's brains aged faster during the COVID pandemic - even the uninfected.
    Nature. 2025 Jul 22. doi: 10.1038/d41586-025-02313.
    PubMed        

  33. RO C
    The COVID-19 pandemic transformed this scientist into a research-integrity sleuth.
    Nature. 2025 Jul 22. doi: 10.1038/d41586-025-01920.
    PubMed        


    Radiology

  34. KETAI L
    Post-COVID-19 Chest CT Expert Consensus, and a Nod to the Law of the Instrument.
    Radiology. 2025;316:e251890.
    PubMed        

  35. YOON SH, Kanne JP, Ashizawa K, Biederer J, et al
    Best Practice: International Multisociety Consensus Statement for Post-COVID-19 Residual Abnormalities on Chest CT Scans.
    Radiology. 2025;316:e243374.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »